

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/828,351	351 04/21/2004		Manja Ahola	TUR-140-A 6705		
32954	7590	10/11/2006	•	EXAMINER		
JAMES C.		DOAD.	TRAN, SUSAN T			
100 DAING SUITE 100	EKFIELD	KUAD		ART UNIT	PAPER NUMBER	
ALEXAND	RIA, VA	22314	1615			

DATE MAILED: 10/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action

Application No.	Applicant(s)
10/828,351	AHOLA ET AL.
Examiner	Art Unit
Susan T. Tran	1615

Advisory Action	10/020,331	AHOLA ET AL.	
Before the Filing of an Appeal Brief	Examiner	Art Unit	
	Susan T. Tran	1615	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence add	ress
THE REPLY FILED 01 September 2006 FAILS TO PLACE THI		•	
<ol> <li>The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Notal Request for Continued Examination (RCE) in compliant time periods:</li> <li>The period for reply expires 3 months from the mailing date</li> </ol>	n the same day as filing a Notice of wing replies: (1) an amendment, affortice of Appeal (with appeal fee) in once with 37 CFR 1.114. The reply most of the final rejection.	Appeal. To avoid aba fidavit, or other eviden compliance with 37 Cl ust be filed within one	nce, which FR 41.31; or (3) of the following
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or	ater than SIX MONTHS from the mailing (b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	on.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7		100() (4)	
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropri inally set in the final Office	ate extension fee ce action; or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed AMENDMENTS</li> </ol>	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	is of the date of e appeal. Since
<ol> <li>The proposed amendment(s) filed after a final rejection,</li> <li>They raise new issues that would require further co</li> <li>They raise the issue of new matter (see NOTE below)</li> </ol>	nsideration and/or search (see NO	, will <u>not</u> be entered be TE below);	ecause
(c) They are not deemed to place the application in be appeal; and/or	tter form for appeal by materially re		the issues for
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.	
4. The amendments are not in compliance with 37 CFR 1.1	21. See attached Notice of Non-Co	empliant Amendment (	(PTOL-324).
<ul> <li>5. Applicant's reply has overcome the following rejection(s)</li> <li>6. Newly proposed or amended claim(s) would be a non-allowable claim(s).</li> </ul>		timely filed amendme	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: <u>29 and 30</u> .	will not be entered, or b)      will not be entered, or b)      will will will will will will will	ll be entered and an e	xplanation of
Claim(s) rejected: <u>23-28 and 31</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).</li> </ol>	d sufficient reasons why the affiday	vit or other evidence is	necessary and
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessar</li> <li>The affidavit or other evidence is entered. An explanation</li> </ol>	overcome <u>all</u> rejections under apper y and was not earlier presented. S	al and/or appellant fai ee 37 CFR 41.33(d)(1	ls to provide a l).
REQUEST FOR RECONSIDERATION/OTHER  11. The request for reconsideration has been considered but	ut does NOT place the application in	n condition for allowar	nce because: `\
12. Note the attached Information Disclosure Statement(s).  13. Other:		•	n)
		Susan T. Tran Primary Examiner Art Unit: 1615	

Art Unit: 1615

Applicant's arguments filed 09/01/06 have been fully considered but they are not persuasive.

Applicant argues that Ducheyne fails to disclose or suggest the complete dissolution of the silica-xerogel, and none of the examples in Ducheyne indicate that its silica glass carriers completely dissolve when in contact with simulated body fluid. In response to applicant's argument that none of the examples in Ducheyne show the carriers completely dissolve when contact with simulated body fluid, it is noted that Ducheyne is relied upon for the teachings within the four-wall patent. Ducheyne cannot be limited to his best mode as described in the examples.

In response to applicant's argument that Ducheyne does not teach the complete dissolution of the silica-xerogel, it is noted that the instant claims do not preclude the bioactive agent to release through the pores of the silica-based gel. Nor, do the instant claims require a total dissolution of the bioactive agent by dissolving the silica-xerogel to completely release the bioactive agent in a very even fashion. Applicant's attention is called to the teaching at column 14, lines 14-37, Ducheyne teaches in order for sol-gel to be an effective carrier for biologically active molecules, sol pH and other factors affect the gelling time of the sol...there are instances when greater porosity may be desirable to achieve a more rapid degradation of the carrier to facilitate the release of larger molecules. Thus, it would have been obvious to one of ordinary skill in the art to modify the porosity of the gel to obtain the desired release rate. Furthermore, even if it were assumed, for the sake of argument, that Ducheyne does not teach the complete dissolution of the silica-xerogel, applicant has not shown any unexpected and/r unusual

Application/Control Number: 10/828,351

Art Unit: 1615

results over the limitation "complete dissolution". This is because Ducheyne teaches the property desired by the applicant, e.g., a carrier for controlled release of biologically active molecules over time. Furthermore, the phrase "controllably releasing said biologically active agent by complete dissolution of said silica-xerogel" is not patently distinct from the prior art. By "controllably release", does it mean the xerogel stay completely unreleasable over a desired period of time, and then quickly and completely dissolved to release the biologically active agent? Hence, the rejection over Ducheyne et al., in view of Einarsrud is maintained.

Page 3